POSSIBILITY OF BONE METABOLISM MODULATOR (STRONTIUM RANELATE) USAGE FOR THE TREATMENT OF WOMEN WITH POSTMENOPAUSAL OSTEOPOROSIS AND ARTERIAL HYPERTENSION

<p><strong>Aim.</strong> To study effect of the bone metabolism modulator strontium ranelate on bone mineral density (BMD) and to evaluate it pleiotropic effects on cardiovascular remodeling in women with postmenopausal osteoporosis (PO) and a arterial hypertension (HT).</p>&...

Full description

Bibliographic Details
Main Authors: N. J. Hozjainova, V. M. Tsareva, T. V. Brook, M. S. Bezaltynnyh
Format: Article
Language:English
Published: Столичная издательская компания 2016-01-01
Series:Рациональная фармакотерапия в кардиологии
Subjects:
Online Access:http://www.rpcardio.ru/jour/article/view/614
_version_ 1827884200547581952
author N. J. Hozjainova
V. M. Tsareva
T. V. Brook
M. S. Bezaltynnyh
author_facet N. J. Hozjainova
V. M. Tsareva
T. V. Brook
M. S. Bezaltynnyh
author_sort N. J. Hozjainova
collection DOAJ
description <p><strong>Aim.</strong> To study effect of the bone metabolism modulator strontium ranelate on bone mineral density (BMD) and to evaluate it pleiotropic effects on cardiovascular remodeling in women with postmenopausal osteoporosis (PO) and a arterial hypertension (HT).</p><p><strong>Material and methods.</strong> 45 women with PO, HT (1-2 stage) and medium/high cardiovascular risk were included in the study. 23 patients of the main group received strontium ranelate 2 g once daily additionally to antihypertensive and calcium replacement therapies. Before therapy and after 10 months MBD was evaluated by dual-energy x-ray absorbtiometry (DEXA) with usage of peripheral densitometer. Strontium ranelate effects on carotid intima-media thickness (duplex scanning) and morphofunctional cardiac indices (echocardiography) also were assessed.</p><p><strong>Results.</strong> Strontium ranelate therapy in patients with PO and HT leads to BMD rising and retardation of cardiovascular remodeling.</p><p><strong>Conclusion.</strong> Strontium ranelate is effective antiosteoporotic drug with positive influence on morphofunctional cardiac indices and carotid intima-media thickness. </p>
first_indexed 2024-03-12T19:25:05Z
format Article
id doaj.art-ba58f80b529d46a5aa1d77b64ca39ee6
institution Directory Open Access Journal
issn 1819-6446
2225-3653
language English
last_indexed 2024-03-12T19:25:05Z
publishDate 2016-01-01
publisher Столичная издательская компания
record_format Article
series Рациональная фармакотерапия в кардиологии
spelling doaj.art-ba58f80b529d46a5aa1d77b64ca39ee62023-08-02T04:56:17ZengСтоличная издательская компанияРациональная фармакотерапия в кардиологии1819-64462225-36532016-01-0152182110.1234/1819-6446-2009-2-18-21613POSSIBILITY OF BONE METABOLISM MODULATOR (STRONTIUM RANELATE) USAGE FOR THE TREATMENT OF WOMEN WITH POSTMENOPAUSAL OSTEOPOROSIS AND ARTERIAL HYPERTENSIONN. J. Hozjainova0V. M. Tsareva1T. V. Brook2M. S. Bezaltynnyh3Смоленская государственная медицинская академия РосздраваСмоленская государственная медицинская академия РосздраваСмоленская государственная медицинская академия РосздраваСмоленская государственная медицинская академия Росздрава<p><strong>Aim.</strong> To study effect of the bone metabolism modulator strontium ranelate on bone mineral density (BMD) and to evaluate it pleiotropic effects on cardiovascular remodeling in women with postmenopausal osteoporosis (PO) and a arterial hypertension (HT).</p><p><strong>Material and methods.</strong> 45 women with PO, HT (1-2 stage) and medium/high cardiovascular risk were included in the study. 23 patients of the main group received strontium ranelate 2 g once daily additionally to antihypertensive and calcium replacement therapies. Before therapy and after 10 months MBD was evaluated by dual-energy x-ray absorbtiometry (DEXA) with usage of peripheral densitometer. Strontium ranelate effects on carotid intima-media thickness (duplex scanning) and morphofunctional cardiac indices (echocardiography) also were assessed.</p><p><strong>Results.</strong> Strontium ranelate therapy in patients with PO and HT leads to BMD rising and retardation of cardiovascular remodeling.</p><p><strong>Conclusion.</strong> Strontium ranelate is effective antiosteoporotic drug with positive influence on morphofunctional cardiac indices and carotid intima-media thickness. </p>http://www.rpcardio.ru/jour/article/view/614стронция ранелатпостменопаузальный остеопорозартериальная гипертониясердечно-сосудистое ремоделирование
spellingShingle N. J. Hozjainova
V. M. Tsareva
T. V. Brook
M. S. Bezaltynnyh
POSSIBILITY OF BONE METABOLISM MODULATOR (STRONTIUM RANELATE) USAGE FOR THE TREATMENT OF WOMEN WITH POSTMENOPAUSAL OSTEOPOROSIS AND ARTERIAL HYPERTENSION
Рациональная фармакотерапия в кардиологии
стронция ранелат
постменопаузальный остеопороз
артериальная гипертония
сердечно-сосудистое ремоделирование
title POSSIBILITY OF BONE METABOLISM MODULATOR (STRONTIUM RANELATE) USAGE FOR THE TREATMENT OF WOMEN WITH POSTMENOPAUSAL OSTEOPOROSIS AND ARTERIAL HYPERTENSION
title_full POSSIBILITY OF BONE METABOLISM MODULATOR (STRONTIUM RANELATE) USAGE FOR THE TREATMENT OF WOMEN WITH POSTMENOPAUSAL OSTEOPOROSIS AND ARTERIAL HYPERTENSION
title_fullStr POSSIBILITY OF BONE METABOLISM MODULATOR (STRONTIUM RANELATE) USAGE FOR THE TREATMENT OF WOMEN WITH POSTMENOPAUSAL OSTEOPOROSIS AND ARTERIAL HYPERTENSION
title_full_unstemmed POSSIBILITY OF BONE METABOLISM MODULATOR (STRONTIUM RANELATE) USAGE FOR THE TREATMENT OF WOMEN WITH POSTMENOPAUSAL OSTEOPOROSIS AND ARTERIAL HYPERTENSION
title_short POSSIBILITY OF BONE METABOLISM MODULATOR (STRONTIUM RANELATE) USAGE FOR THE TREATMENT OF WOMEN WITH POSTMENOPAUSAL OSTEOPOROSIS AND ARTERIAL HYPERTENSION
title_sort possibility of bone metabolism modulator strontium ranelate usage for the treatment of women with postmenopausal osteoporosis and arterial hypertension
topic стронция ранелат
постменопаузальный остеопороз
артериальная гипертония
сердечно-сосудистое ремоделирование
url http://www.rpcardio.ru/jour/article/view/614
work_keys_str_mv AT njhozjainova possibilityofbonemetabolismmodulatorstrontiumranelateusageforthetreatmentofwomenwithpostmenopausalosteoporosisandarterialhypertension
AT vmtsareva possibilityofbonemetabolismmodulatorstrontiumranelateusageforthetreatmentofwomenwithpostmenopausalosteoporosisandarterialhypertension
AT tvbrook possibilityofbonemetabolismmodulatorstrontiumranelateusageforthetreatmentofwomenwithpostmenopausalosteoporosisandarterialhypertension
AT msbezaltynnyh possibilityofbonemetabolismmodulatorstrontiumranelateusageforthetreatmentofwomenwithpostmenopausalosteoporosisandarterialhypertension